Gastrointestinal stromal tumors: chemotherapy and
In Rare Tumors, 2001
... (PDGFR-β, 1:100, Calbiochem, Schwalbach/Ts, Germany), and stem cell tyrosine kinase 1 (FLT3, 1:100, Abcam, Cambridge, UK), as ...
Molecular therapy for acute myeloid leukaemia.
New York City, United States. In Nat Rev Clin Oncol, Jan 2016
Indeed, risk status in patients with this disease has classically been based on cytogenetic findings; however, additional molecular characteristics have been shown to inform risk assessment, including FLT3, NPM1, KIT, and CEBPA mutation status.
INFERENCE OF PERSONALIZED DRUG TARGETS VIA NETWORK PROPAGATION.
Tel Aviv-Yafo, Israel. In Pac Symp Biocomput, Dec 2015
Finally, we focus on the largest AML patient subgroup (~30%) which is characterized by an FLT3 mutation, and utilize our prediction score to rank patient sensitivity to inhibition of each predicted target, reproducing previous findings of in-vitro experiments.